Polyphor N Aktie
WKN: A2JK4Q
ISIN: CH0106213793
Land: Sonstiges
Branche: Sonstiges
Sektor: Sonstiges
Gratis: Die zehn beliebtesten Rüstungs-Aktien im Check! Info...
0,0000 EUR 0,0000  EUR 0,00  %
Komplette Navigation anzeigen

News und Analysen

Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.

Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.

Spexis AG / Key word(s): Miscellaneous Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially ...weiterlesen

22.07.24
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
08.07.24
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiotix, Inc.
04.06.24
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
31.05.24
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
30.04.24
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. 
17.04.24
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
08.02.24
Spexis announces closing of sale of preclinical antibiotics program to Basilea
15.01.24
Spexis announces sale of preclinical antibiotics program to Basilea
05.12.23
Spexis is Granted Debt-Restructuring Moratorium
Seite: 1 | 2 | ►

Jetzt neu: